NCHR Testimony on Avastin

July 20, 2010. It is clear that the benefits do not outweigh the risks and that the indication for treatment of metastic breast cancer should be REMOVED from the Avastin label.

Read More »

Testimony on Acurox

April 22, 2010. Although Acura Pharmaceuticals should be applauded for trying to reduce the misuse and abuse of oxycondone, the key question is: can Acurox easily be abused?

Read More »